The historical rank and industry rank for InMed Pharmaceuticals's OCF Margin % or its related term are showing as below:
FRA:MWG'
s OCF Margin % Range Over the Past 10 Years
Min: -1431.04 Med: -166.61 Max: -151.94
Current: -107.86
During the past 13 years, the highest OCF Margin % of InMed Pharmaceuticals was -151.94%. The lowest was -1431.04%. And the median was -166.61%.
FRA:MWG's OCF Margin % is ranked worse than 93.12% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs FRA:MWG: -107.86
InMed Pharmaceuticals OCF Margin % Related Terms
InMed Pharmaceuticals OCF Margin % Historical Data
* Premium members only.
The historical data trend for InMed Pharmaceuticals's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:MWG vs GELS, LVRLF, BUDZ: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InMed Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (FRA:MWG) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on InMed Pharmaceuticals and its competitors. According to the industry distribution chart, InMed Pharmaceuticals ranks #893 out of 959 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is InMed Pharmaceuticals' OCF Margin % too high?
InMed Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, InMed Pharmaceuticals ranks #893 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' OCF Margin % compare to GELS and LVRLF?
According to the Drug Manufacturers industry distribution chart, InMed Pharmaceuticals ranks #893 out of 959 companies for OCF Margin %. This places InMed Pharmaceuticals in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on InMed Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InMed Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (FRA:MWG) has a current OCF Margin % of 0.00%. The stock's GF Value™ is €0.78, compared to a current price of €1.26 — trading 61.5% above its estimated fair value. The current OCF Margin % is 0.00%. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?
Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued.
The current stock price of €1.26 is trading 61.5% above its estimated GF Value™ of €0.78.
Key valuation signals for FRA:MWG:
OCF Margin %: 0.00%
GF Value™: €0.78 vs. price of €1.26 (61.5% above fair value)
No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score
Get the complete analysis for FRA:MWG
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MWG has been successfully added to your 
